أرسل هذا في رسالة قصيرة: Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials

  ______    ______  __    __    _____     _____   
 /_   _//  /_   _// \ \\ / //  |  ___||  /  ___|| 
 `-| |,-    -| ||-   \ \/ //   | ||__   | // __   
   | ||     _| ||_    \  //    | ||__   | \\_\ || 
   |_||    /_____//    \//     |_____||  \____//  
   `-`'    `-----`      `      `-----`    `---`